NAD+ injection side effects: what the panic-attack feeling really means
A TikTok creator describes the first NAD+ injection as feeling like a mild panic attack. We examine what the research says about NAD+ infusion reactions and why flushing and a racing heart are common.
A recent TikTok clip shows a user describing their first experience injecting NAD+. They report a racing heart, flushing, and lightheadedness—sensations they compare to a panic attack. The creator frames these effects as mild and even suggests they signal the therapy is working. But is that interpretation supported by evidence, or is it an oversimplification of a complex biological response?
What the clip is claiming
The clip’s core claim is that the unpleasant sensations after an NAD+ injection are both normal and a positive indicator of efficacy. The creator explicitly says, “It tells you it’s working,” implying a direct link between the side-effect profile and therapeutic benefit. This is a common narrative in wellness circles, but it conflates a physiological reaction with a clinical outcome.
What the research neighborhood actually covers
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular energy metabolism and has been studied for its potential roles in aging, neurodegeneration, and metabolic health. However, the research on NAD+ supplementation—especially via injection—is still in early stages. Most clinical studies use oral precursors like nicotinamide riboside or nicotinamide mononucleotide, not injectable NAD+. The limited data on intravenous NAD+ suggest that flushing, headache, and gastrointestinal discomfort are common, but these are typically attributed to a histamine release or a temporary drop in blood pressure, not to the molecule’s metabolic effects.
Flushing and a racing heart are classic signs of niacin (vitamin B3) exposure, which can occur as a byproduct of NAD+ breakdown. Niacin causes vasodilation by releasing prostaglandins, leading to a warm, red sensation. This is a well-documented pharmacological effect, not a marker of cellular repair. Lightheadedness may result from a transient drop in blood pressure. These reactions are generally mild and transient, but they are not evidence that NAD+ is “working” in the way the clip suggests.
Limits, missing context, and what a 15-second clip cannot show
The clip lacks critical context. First, it does not specify the dose, the rate of injection, or whether the user was fasting or hydrated—all factors that influence side-effect severity. Second, it does not mention that such reactions are more common with rapid infusion; slower administration can minimize them. Third, the creator’s anecdote is a single data point, not a clinical trial. Individual responses vary widely, and some people may experience more severe reactions, including anxiety or palpitations, that are not “mild” to them.
Moreover, the claim that side effects indicate efficacy is not supported by research. In clinical studies, the presence of flushing does not correlate with improved outcomes. For example, niacin-induced flushing is not a predictor of cholesterol-lowering benefit. Similarly, NAD+ side effects are likely a nuisance, not a signal of success. A 15-second clip cannot convey the nuance of dose-response relationships or the difference between acute reactions and long-term benefits.
How this maps to research compounds
This clip is specifically about NAD+, which is a catalog compound. In the research-use context, NAD+ is often studied for its role in sirtuin activation and mitochondrial function. However, the injection experience described is not unique to NAD+; similar flushing reactions can occur with other compounds that affect vascular tone, such as niacinamide or even some peptides. But the clip does not mention any other compound, so we focus solely on NAD+.
For researchers, the key takeaway is that NAD+ administration in animal models or human trials requires careful monitoring of vital signs and infusion rates. The “panic attack” feeling is likely a vasovagal or histamine-mediated response, not a direct measure of NAD+ bioavailability or efficacy. Future studies should separate the acute side-effect profile from the long-term metabolic outcomes.
Research-use caveat
This article is for informational purposes only and does not constitute medical advice. NAD+ and other research compounds are intended for laboratory and investigational use only, not for human consumption. Always consult a qualified healthcare provider for any health-related concerns.
Open the full video fact-check page (transcript, takeaways, embedded clip).